Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/cid/ciaa1563 http://scihub22266oqcxt.onion/10.1093/cid/ciaa1563 33053155!7665361!33053155     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33053155&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Clin+Infect+Dis 2021 ; 72 (11): e887-e889 Nephropedia Template TP {{tp|p=33053155|t=2021. Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies |pdf=|usr=}}{{33053155}} gab.com Text Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies JO: Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33053155 #FOAvip For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported. Twit Text FOAVip Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies ????Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33053155 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33053155 #FOAvip English Wikipedia <ref>{{Cite pmid|33053155}}</ref> Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies #MMPMID33053155 McCaw ZR; Tian L; Kim DH; Localio AR; Wei LJ Clin Infect Dis 2021[Jun]; 72 (11): e887-e889 PMID33053155show ga For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported. |*COVID-19[MESH] |Humans[MESH] |Proportional Hazards Models[MESH] |SARS-CoV-2[MESH] |Survival Analysis[MESH]Survival Analysis of Treatment Efficacy in Comparative Coronavirus Dis(epmc).pdf DeepDyve Pubget Overpricing